Trivalent Salmonella Conjugate Vaccine (TSCV)

Age-descending, Randomized, Placebo-controlled Phase 2 Trial in Three Sites in Sub-Saharan Africa to Assess the Safety and Immunogenicity of a Parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) Versus Placebo

This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.

Study Overview

• Status: Recruiting
• Conditions: Trivalent Salmonella Conjugate Vaccine (TSCV)
• Intervention / Treatment: Drug: Placebo; Drug: TSCV (Full-strength); Drug: TSCV (Half-strength); Drug: Typbar-TCV

Detailed Description

This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.

In Step 1A-D of the trial, participants will be randomized to receive a single dose of TSCV (Full-strength or Half-strength), Typbar-TCV, or placebo, first in adults, then in children 5 to 9 years of age, then children 24 to 59 months of age, and then 16 to 23 months of age.

Participants will be followed for 6 months. After a Data Safety Monitoring Board (DSMB) review of the safety data, the trial will proceed to Step 2A and 2B whereupon 12- to 16-month-old toddlers and infants 8- to 11-months of age will be similarly and simultaneously randomized. Participants will be followed for 6 months.

After another DSMB safety review, Step 3 will commence with simultaneous enrollment of 12- to 14-week-old and 16- to 18-week-old infants who will each receive a single dose of TSCV, TCV or placebo. Participants will be followed for 6 months.

After a third DSMB safety review and selection of the preferred TSCV formulation (Full-strength versus Half-strength) for further clinical development (a decision taken by the Sponsor, Manufacturer, and funder, while taking into consideration the recommendation of the DSMB), Step 4 will evaluate a two-dose regimen. Infants 12 to 18 weeks of age will be randomized to receive either two doses of TSCV (at Full-strength or Half-strength, based on results from Steps 1-3) or placebo followed by Typbar-TCV. The priming dose will be administered at enrollment and the booster at ~9, ~12, or ~15-17 months of age.

Participants will be followed until 6 months after the last study vaccination.

Note -- Whenever investigational products are intended to be administered at a scheduled Expanded Program on Immunization visit, they will always be given 2 weeks after the routine EPI vaccines. This will not only avoid interference with EPI vaccines but will provide a convenient contact point for potential recruitment of participants for the study.

• Study Type: Interventional
• Enrollment (Estimated): 800
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Alyson Kwon; Email: akwon@som.umaryland.edu
• Study Contact Backup: Name: Fleesie Hubbard; Phone Number: 410-706-0850; Email: fhubbard@som.umaryland.edu

Study Locations

• Mali
  • Bamako, Mali
    • Recruiting
    • Centre for Vaccine Development (CVD-Mali)
    • Principal Investigator: Samba Sow, MD
    • Contact: Fatoumata Diallo, MD; Phone Number: 7460 1819; Email: fdiallo@cvd-mali.org
    • Contact: Youssouf Traore, MD; Phone Number: 6182 5843

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 months to 35 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy individuals, female or male

• Age (all age ranges are inclusive)

  1. Step 1A: Adults 20-35 years of age
  2. Step 1B: Children, 5-9 years of age
  3. Step 1 C: Pre-school children, 24-59 mos. of age
  4. Step 1D: Older toddlers, 16-23 months of age
  5. Step 2A: Young toddlers, 12-16 months of age
  6. Step 2B: Older infants, 8-11 months of age
  7. Step 3: Young infants,12-14 weeks of age OR 16-18 weeks of age
  8. Step 4: Young infants, 12-18 weeks of age
• For potential pediatric participants, the parents must live within the catchment area of the clinical study facility at the time of the study vaccinations and must intend to continue to reside in the area for the duration of the study
• Adult subjects and parents/ guardians of pediatric subjects must have provided informed consent
• Infant and toddler subjects in Steps 2, 3, and 4 must have received their scheduled EPI vaccines at least 14 days prior to receiving a study product.

Exclusion Criteria:

• A history of documented hypersensitivity to any component of the Trivalent Salmonella Conjugate Vaccine or of Typbar-TCV™
• A history of previous vaccination with any licensed or experimental typhoid vaccine A known history of diabetes, tuberculosis, malignancy, chronic kidney disease, cardiac disease, liver disease, progressive neurological disorder, poorly controlled seizure disorder, or a terminal illness based on participant interview and review of screening laboratory results.
• Severe malnutrition: i.e., weight-for-length Z-score of less than - 3.
• Receipt of any other investigational intervention in the last 6 months
• Known HIV infection or other forms of immunocompromise
• Receipt of systemic immunosuppressive medication including systemic corticosteroids
• For Step 1A, for females of child-bearing potential, a positive pregnancy test at the time of enrollment.
• For Step 1B, any female child who has experienced menarche.
• Acute illness with or without fever (temperature >38.0oC) is a temporary exclusion criterion. Enrollment may be postponed until 3 days after the illness has resolved.
• Positive malaria test is a temporary exclusion criterion. Participant may be enrolled 3 days after completing treatment.
• Any condition determined by the investigators to be likely to interfere with evaluation of the vaccine, to be a significant health risk to the participant, or to make it unlikely that the participant would complete the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; PBS	Drug: Placebo; Placebo
Active Comparator: TSCV (Full-strength); Full-strength GMP formulation of Trivalent Salmonella Conjugate Vaccine (TSCV)	Drug: TSCV (Full-strength); TSCV (Full-strength)
Active Comparator: TSCV (Half-strength); Half-strength GMP formulation of TSCV	Drug: TSCV (Half-strength); TSCV (Half-strength)
Active Comparator: Typbar-TCV; Licensed Monovalent Typbar-TCV	Drug: Typbar-TCV; Typbar-TCV

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and reactogenicity of Full-strength and Half-strength TSCV	The proportion of participants in each product group and within each age group who develop adverse events (AEs) in the first 30 minutes after parenteral immunization	first 30 minutes after parenteral immunization
Safety and reactogenicity of Full-strength and Half-strength TSCV	The proportion of participants in each product group and within each age group who develop adverse events (AEs) in the 7 days post-vaccination.	over 7 days post-vaccination.
Safety and reactogenicity of Full-strength and Half-strength TSCV	The proportion of participants who experience AEs through Day 29 of follow-up post-vaccination.	through Day 29 of follow-up post-vaccination
Safety and reactogenicity of Full-strength and Half-strength TSCV	The proportion of participants who experience Serious Adverse Events through their participation in the study.	Through Day 366 of follow-up post vaccination
Non-inferiority analysis: immunogenicity of Full-strength vs. Half-strength TSCV	Serum IgG anti-COPS antibodies (to both S. Enteritidis and S. Typhimurium antigens)	Through day 29 post vaccination
Non-inferiority analysis: immunogenicity of Full-strength vs. Half-strength TSCV	Serum IgG anti-Vi antibodies	Through day 29 post vaccination
Safety and reactogenicity after primary dose of TSCV and after booster dose of TSCV or Typbar-TCV™ [At each booster age group (9, 12, or 15-17 mo. of age)]	The proportion of participants in each product group who develop adverse events (AEs) in 7 days post-vaccination.	over 7 days post-vaccination.
Safety and reactogenicity after primary dose of TSCV and after booster dose of TSCV or Typbar-TCV™ [At each booster age group (9, 12, or 15-17 mo. of age)]	The proportion of participants who experience AEs through Day 29 of follow-up after each vaccination.	through Day 29 of follow-up after each vaccination.
Safety and reactogenicity after primary dose of TSCV and after booster dose of TSCV or Typbar-TCV™ [At each booster age group (9, 12, or 15-17 mo. of age)]	The proportion of participants who experience Serious Adverse Events through their participation in the study.	Until the end of the participant study period - 6 months to 1 year post vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]	The rates of seroconversion of serum IgG anti-COPS at each booster age group	At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]	The geometric mean titers of serum IgG anti-COPS at each booster age group	At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]	The increases in geometric mean-fold titers from day 1 to 29 of serum IgG anti-COPS at each booster age group	At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]	The rates of persisting seroconversion (titers remaining > 4-fold above Day 1) of serum IgG anti-COPS at each booster age group	At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]	The rates of seroconversion of serum IgG anti-Vi at each booster age group	At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]	The geometric mean titers of serum IgG anti-Vi at each booster age group	At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]	The increases in geometric mean-fold titers from day 1 to 29 of serum IgG anti-Vi at each booster age group	At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]	The rates of persisting seroconversion (titers remaining > 4-fold above Day 1) of serum IgG anti-Vi at each booster age group	At day 29 post booster vaccination

Collaborators and Investigators

• Sponsor: University of Maryland, Baltimore
• Collaborators: Wellcome Trust; Bharat Biotech International
• Investigators: Principal Investigator: Miligritos Tapia, MD, University of Maryland Center for Vaccine Development

Study record dates

Study Major Dates

• Study Start (Actual): April 5, 2023
• Primary Completion (Estimated): January 5, 2027
• Study Completion (Estimated): December 30, 2027

Study Registration Dates

• First Submitted: February 7, 2023
• First Submitted That Met QC Criteria: March 13, 2023
• First Posted (Actual): March 27, 2023

Study Record Updates

• Last Update Posted (Actual): May 2, 2025
• Last Update Submitted That Met QC Criteria: April 29, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: S. Enteritidis; S. Typhimurium; S. Typhi Vi; Trivalent Salmonella Conjugate Vaccine (TSCV)
• Other Study ID Numbers: HP-00103997

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No